Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review

Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) show high rates of cardiorenal outcomes. In addition, the progression towards renal failure and cardiovascular events rises as CKD worsens. Several studies suggest that the activation of the mineralocorticoid receptor (MR) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Piccirillo, Francesco, Liporace, Paola, Nusca, Annunziata, Nafisio, Vincenzo, Corlianò, Andrea, Magarò, Francesca, Antonelli Incalzi, Raffaele, Ussia, Gian Paolo, Grigioni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299623/
https://www.ncbi.nlm.nih.gov/pubmed/37367401
http://dx.doi.org/10.3390/jcdd10060236
_version_ 1785064409959235584
author Piccirillo, Francesco
Liporace, Paola
Nusca, Annunziata
Nafisio, Vincenzo
Corlianò, Andrea
Magarò, Francesca
Antonelli Incalzi, Raffaele
Ussia, Gian Paolo
Grigioni, Francesco
author_facet Piccirillo, Francesco
Liporace, Paola
Nusca, Annunziata
Nafisio, Vincenzo
Corlianò, Andrea
Magarò, Francesca
Antonelli Incalzi, Raffaele
Ussia, Gian Paolo
Grigioni, Francesco
author_sort Piccirillo, Francesco
collection PubMed
description Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) show high rates of cardiorenal outcomes. In addition, the progression towards renal failure and cardiovascular events rises as CKD worsens. Several studies suggest that the activation of the mineralocorticoid receptor (MR) induces cardiac and renal injury, including inflammation and fibrosis. Finerenone is a novel, nonsteroidal, selective MR antagonist (MRA) which has demonstrated anti-inflammatory and anti-fibrotic effects in pre-clinical studies. Moreover, two large trials (FIDELIO-DKD and FIGARO-DKD) investigated the renal and cardiovascular outcomes in patients with mild to severe CKD in type 2 diabetes which received finerenone. On these bases, this comprehensive review aims to summarize the current knowledge regarding finerenone and its effects on CKD and the cardiovascular system, emphasizing its role in modifying cardiorenal outcomes.
format Online
Article
Text
id pubmed-10299623
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102996232023-06-28 Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review Piccirillo, Francesco Liporace, Paola Nusca, Annunziata Nafisio, Vincenzo Corlianò, Andrea Magarò, Francesca Antonelli Incalzi, Raffaele Ussia, Gian Paolo Grigioni, Francesco J Cardiovasc Dev Dis Review Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) show high rates of cardiorenal outcomes. In addition, the progression towards renal failure and cardiovascular events rises as CKD worsens. Several studies suggest that the activation of the mineralocorticoid receptor (MR) induces cardiac and renal injury, including inflammation and fibrosis. Finerenone is a novel, nonsteroidal, selective MR antagonist (MRA) which has demonstrated anti-inflammatory and anti-fibrotic effects in pre-clinical studies. Moreover, two large trials (FIDELIO-DKD and FIGARO-DKD) investigated the renal and cardiovascular outcomes in patients with mild to severe CKD in type 2 diabetes which received finerenone. On these bases, this comprehensive review aims to summarize the current knowledge regarding finerenone and its effects on CKD and the cardiovascular system, emphasizing its role in modifying cardiorenal outcomes. MDPI 2023-05-28 /pmc/articles/PMC10299623/ /pubmed/37367401 http://dx.doi.org/10.3390/jcdd10060236 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Piccirillo, Francesco
Liporace, Paola
Nusca, Annunziata
Nafisio, Vincenzo
Corlianò, Andrea
Magarò, Francesca
Antonelli Incalzi, Raffaele
Ussia, Gian Paolo
Grigioni, Francesco
Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review
title Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review
title_full Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review
title_fullStr Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review
title_full_unstemmed Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review
title_short Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive Review
title_sort effects of finerenone on cardiovascular and chronic kidney diseases: a new weapon against cardiorenal morbidity and mortality—a comprehensive review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299623/
https://www.ncbi.nlm.nih.gov/pubmed/37367401
http://dx.doi.org/10.3390/jcdd10060236
work_keys_str_mv AT piccirillofrancesco effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview
AT liporacepaola effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview
AT nuscaannunziata effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview
AT nafisiovincenzo effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview
AT corlianoandrea effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview
AT magarofrancesca effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview
AT antonelliincalziraffaele effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview
AT ussiagianpaolo effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview
AT grigionifrancesco effectsoffinerenoneoncardiovascularandchronickidneydiseasesanewweaponagainstcardiorenalmorbidityandmortalityacomprehensivereview

Ejemplares similares